Acute myeloid leukemia in the older patient

Critical Reviews in Oncology/Hematology

Volumn 48, Issue SUPPL., 2003, Pages

  Godwin, John E ^a   Smith, Scott E ^a  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

Acute myeloid leukemia; AML biology; AML pathogenesis; G CSF; GM CSF; Growth factors

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; AGING; BONE PAIN; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; FEVER; GERIATRIC CARE; HUMAN; MOLECULAR DYNAMICS; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; UNITED STATES;

EID: 0141963162     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2003.04.007     Document Type: Conference Paper

References (57)

1. Till J.E., McCulloch E.A. A direct measurement of the radiosensitivity of normal mouse bone marrow cells. Radiat. Res. 14:1961;213-222.
2. Guenechea G., Gan O.I., Dorrell C., Dick J.E. Distinct classes of human stem cells that differ in proliferative and self-renewal potential. Nat. Immunol. 2:2001;75-82.
3. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3:1997;730-737.
4. Bennett J.M., Catovsky D., Daniel M.T.et al. Proposals for the classification of acute leukemias. Br. J. Haematol. 33:1976;451-458.
5. Bennett J.M., Catovsky D., Daniel M.T.et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann. Intern. Med. 103:1985;620-625.
6. Bennett J.M., Catovsky D., Daniel M.T.et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7): a report of the French-American-British Cooperative Group. Ann. Intern. Med. 103:1985;460-462.
7. Bennett J.M., Catovsky D., Daniel M.T.et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br. J. Haematol. 78:1991;325-329.
8. Rowley J.D.et al. Chromosome changes in acute leukaemia. Br. J. Haematol. 44:1980;339-346.
9. Bitter M.A., Le Beau M.M., Rowley J.D., Larson R.A., Golomb H.M., Vardiman J.W. Associations between morphology, karyotype, and clinical features in myeloid leukemias. Hum. Pathol. 18:1987;211-225.
10. Kelly L.M., Gilliland D.G. Genetics of myeloid leukemias. Annu. Rev. Genomics. Hum. Genet. 3:2002;179-198.
11. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 61:1990;203-212.
12. Rosnet O., Birnbaum D. Hematopoietic receptors of class III receptor-type tyrosine kinases. Crit. Rev. Oncol. 4:1993;595-613.
13. Appelbaum F.R., Rowe J.M., Radich J., Dick J.E. Acute myeloid leukemia. Hematology (Am. Soc. Hematol. Educ. Program). 1:2001;62-86.
14. Brendel C., Neubauer A. Characteristics and analysis of normal and leukemic stem cells: current concepts and future directions. Leukemia. 14:2000;1711-1717.
15. McCulloch E. Toward a leukemia treatment strategy based on the probability of stem cell death: an essay in honor of Dr. Emil J. Freireich. Clin. Cancer Res. 3:1997;2676-2681.
16. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3(7):1997;730-737.
17. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics, 2002. CA Cancer J. Clin. 52:2002;23-47.
18. Edwards B.K., Howe H.L., Ries L.A.G.et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden. Cancer. 94:2002;2766-2792.
19. Appelbaum F.R., Rowe J.M., Radich J., Dick J.E. Acute myeloid leukemia. Hematology (Am. Soc. Hematol. Educ. Program). 1:2001;62-86.
20. Lichtman M.A. The stem cell in the pathogenesis and treatment of myelogenous leukemia: a perspective. Leukemia. 15(10):2001;1489-1494.
21. Bennett J.M., Young M.L., Andersen J.W.et al. Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience. Cancer. 80(11 Suppl.):1997;2205-2209.
22. Leith C.P., Kopecky K.J., Godwin J.et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 89(9):1997;3323-3329.
23. Harousseau J.L. Acute myeloid leukemia in the elderly. Blood Rev. 12(3):1998;145-153.
24. Grimwade D., Walker E., Harrison G.et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 98(5):2001;1312-1320.
25. Leith C.P., Kopecky K.J., Chen I.-M.et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group study. Blood. 94:1999;1086-1099.
26. Head D.R. Revised classification of acute myeloid leukemia. Leukemia. 10(11):1996;1826-1831.
27. Cuneo A., Bigoni R., Cavazzini F.et al. Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype. Leukemia. 16(9):2002;1745-1751.
28. Kiyoi H., Naoe T., Yokota S.et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia. 11:1997;1447-1452.
29. Yokota S., Kiyoi H., Nakao M.et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia. 11:1997;1605-1609.
30. Meshinchi S., Woods W.G., Stirewalt D.L.et al. Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 97:2001;89-94.
31. Stirewalt D.L., Kopecky K.J., Meshinchi S.et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 97:2001;3589-3595.
32. Mayer R.J., Davis R.B., Schiffer C.A.et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med. 331(14):1994;896-903.
33. Vellenga E., Young D.C., Wagner K., Wiper D., Ostapovicz D., Griffin J.D. The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood. 69:1987;1771-1776.
34. Gore S.D., Weng L.J., Burke P.J. Identification of growth factor responsive acute myelogenous leukemia based on factor-dependence for survival and proliferation. Leukemia. 8:1994;1854-1863.
35. Büchner T., Hiddemann W., Koenigsmann M.et al. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood. 78:1991;1190-1197.
36. Bettelheim P., Valent P., Andreeff M.et al. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood. 77:1991;700-711.
37. Ohno R., Tomonaga M., Kobayashi T.et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N. Engl. J. Med. 323:1990;871-877.
38. Rowe J.M., Andersen J., Mazza J.J.et al. A randomized placebo-controlled study of granulocyte-macrophage colony stimulating factor in adult patients (>55-70 years of age) with acute myelogenous leukemia (AML): a study of the Eastern Cooperative Oncology Group (E1490). Blood. 86:1995;457-462.
39. Stone R.M., Berg D.T., George S.L.et al. For the Cancer and Leukemia Group B. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N. Engl. J. Med. 332:1995;1671-1677.
40. Godwin J.E., Kopecky K.J., Head D.R.et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031). Blood. 91:1998;3607-3615.
41. Dombret H., Chastang C., Fenaux P.et al. A controlled study of recombinant human granulocyte colonystimulating factor in elderly patents after treatment for acute myelogenous leukemia. N. Engl. J. Med. 332:1995;1678-1683.
42. Löwenberg B., Sucius S., Archimbaud E.et al. Use of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of the European Organization for the Research and Treatment of Cancer (EORTC-LLG) and the Dutch-Belgium Hemato-Oncology Cooperative Group (HOVON). Blood. 90:1997;2952-2961.
43. Witz F., Sadoun A., Perrin M.-C.et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood. 91:1998;2722-2730.
44. Goldstone A.H., Burnett A.K., Wheatley K., Smith A.G., Hutchinson R.M., Clark R.E. On behalf of the Medical Research Council Adult Leukaemia Working Party. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 98:2001;1302-1313.
45. Zittoun R., Sucius S., Mandelli F.et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J. Clin. Oncol. 14:1996;2150-2159.
46. Heil G., Hoelzer D., Sanz M.A.et al. A randomized, double-blind placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood. 90:1997;4710-4718.
47. Schiffer C.A. Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood. 88:1996;3675-3685.
48. Geller R.B. Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. J. Clin. Oncol. 14(4):1996;1371-1382.
49. Price T.H., Chatta G.S., Dale D.C. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood. 88:1996;335-340.
50. Ozer H., Armitage J.O., Bennett C.L.et al. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J. Clin. Oncol. 18(20):2000;3558-3585.
51. Bennett C.L., Stinson T.J., Tallman M.S.et al. Economic analysis of a randomized, placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients with acute myelogenous leukemia. Ann. Oncol. 10:1999;177-182.
52. Bennett C.L., Hynes D., Godwin J., Stinson T.J., Golub R.M., Appelbaum F.R. Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group Clinical Trial. Cancer Invest. 19(6):2001;603-610.
53. Bhalla K., Birkhofer M., Arlin A.et al. Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. Leukemia. 2:1988;810-813.
54. Ohno R., Naoe T., Kanamaru A.et al. A double-blind controlled study of granulocyte-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia: Kohseisho Leukemia Study Group. Blood. 83:1994;2086-2092.
55. Zittoun R., Suciu S., Mandelli F.et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J. Clin. Oncol. 14:1996;2150-2159.
56. Lowenberg B., Boogaerts M.A., Daenen S.M.G.J.et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J. Clin. Oncol. 15:1997;3496-3506.
57. Lowenberg B., Suciu S., Archimbaud E.et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-111, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Group. Blood. 90:1997;2952-2961.